source
- Eli Lilly and Resilience commit $750 million to expand U.S. KwikPen device capacity for diabetes and obesity treatmentsEli Lilly and contract development and manufacturing organization Resilience have announced a $750 million investment to boost U.S. production of the KwikPen device that delivers Lilly’s injectable…
- Moderna sticks to 10% revenue growth goal despite Phase 3 norovirus vaccine missModerna said it will continue to aim for up to 10% revenue growth this year, even though its experimental norovirus vaccine did not achieve statistical significance in a Phase 3 interim analysis.…